If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 36

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer, Colorectal, Gynecologic Cancers, Esophagus, Other Urologic, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Esophagus, Skin Cancers, Stomach, Prostate and Urologic Cancers, Pancreas/Liver, Breast Cancers, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Lung, Thoracic Cancers

REMASTer: REcurrent Brain Metastases After SRS Trial

Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer, Endocrine Cancers, Uterine, Other Urologic, Colorectal, Cervix, Lung, Brain and Spine Cancers, Prostate, Stomach, Skin Cancers, Prostate and Urologic Cancers, Other Respiratory, Gastrointestinal Cancers, Breast Cancers, Head and Neck Cancers, Esophagus, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Gynecologic Cancers, Sarcoma, Eye/Orbital Cancers

A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors

Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
Categories
Cancer, Gynecologic Cancers, Thoracic Cancers, Colorectal, Early Phase/Multiple Disease Site Cancers, Kidney, Other Skin, Pancreas/Liver, Other Urologic, Prostate and Urologic Cancers, Stomach, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Sarcoma, Breast Cancers

Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer

Objective
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
Categories
Cancer, Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer, Other Skin, Bladder, Colorectal, Cervix, Other Gynecologic, Breast Cancers, Esophagus, Prostate, Larynx, Other Gastrointestinal, Esophagus, Gynecologic Cancers, Other Respiratory, Melanoma, Skin, Prostate and Urologic Cancers, Pancreas/Liver, Eye/Orbital Cancers, Thoracic Cancers, Lip, Oral Cavity and Pharynx, Head and Neck Cancers, Gastrointestinal Cancers, Endocrine Cancers, Skin Cancers, Brain and Spine Cancers

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Objective
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Protocol No
SWOG-S2012
Categories
Cancer, Colorectal, Other Gastrointestinal, Prostate, Pancreas/Liver, Ovary, Early Phase/Multiple Disease Site Cancers, Bladder, Prostate and Urologic Cancers, Gynecologic Cancers, Gastrointestinal Cancers

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer, Stomach, Prostate, Breast Cancers, Other Skin, Lip, Oral Cavity and Pharynx, Larynx, Ovary, Head and Neck Cancers, Thoracic Cancers, Sarcoma, Other Urologic, Pancreas/Liver, Cervix, Gynecologic Cancers, Esophagus, Melanoma, Skin, Bladder, Gastrointestinal Cancers, Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers, Skin Cancers